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Experience with exercise right heart
catheterization in the diagnosis of pulmonary
hypertension: a retrospective study
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Abstract
Background: Data on exercise pulmonary hemodynamics in healthy people and patients with pulmonary
hypertension (PH) are rare. We analyzed exercise right heart catheterization (RHC) data in a symptomatic collective
referred with suspected PH to characterize the differential response by diagnostic groups, to correlate resting with
exercise hemodynamics, and to evaluate safety.
Methods: This is a retrospective single-center study reviewing data from patients in whom an exercise RHC was
performed between January 2006 and January 2013. Patients with follow-up RHC under PH -therapy were excluded.
Results: Data from 101 patients were analyzed, none of them had an adverse event. In 35% we detected a resting
PH (27.8% precapillary, 6.9% postcapillary). Exercise PH (mean pulmonary arterial pressure (mPAP) >30 mmHg at
exercise) was found in 38.6%, whereas in 25.7% PH was excluded. We found a remarkable number of exercise PH in
scleroderma patients, the majority being postcapillary. 83% of patients with mPAP-values between 20 and 24.9 mmHg
at rest had exercise PH. Patients with resting PH had worse hemodynamics and were older compared with exercise PH
ones.
Conclusion: In this real-life experience in symptomatic patients undergoing exercise RHC for suspected PH, we found
that exercise RHC is safe. The facts that the vast majority of patients with mPAP-values between 20 and 24.9 mmHg at
rest had exercise PH and the older age of patients with resting PH may indicate that exercise PH is a precursor of resting
PH. Whether earlier treatment start in patients with exercise PH would stabilize the disease should be addressed in
future studies.
Keywords: Exercise, Pulmonary arterial hypertension, Pulmonary hypertension, Right heart catheterization
Background
Pulmonary hypertension (PH) is defined as a mean pul-
monary artery pressure (mPAP) ≥25 mmHg during resting
right heart catheterization (RHC) in supine position for at
least 15 minutes [1]. PH may occur in association with
various diseases, but also without any obvious reason
(idiopathic). PH has been classified by the World Health
Organization (WHO) in 5 classes, namely pulmonary ar-
terial hypertension (class I), PH owing to left heart disease
(class II), pulmonary hypertension due to lung diseases
and/or hypoxia (class III), chronic thromboembolic PH
(class IV) and PH with unclear multifactorial mechanisms
(class V) [2]. PH can only be safely diagnosed invasively by
right heart catheterization. Hereby, precapillary PH can be
separated from pulmonary venous hypertension by meas-
urement of the pulmonary artery wedge pressure (PAWP).
The cardinal symptom of patients suffering from all
forms of PH is exertional dyspnea. This is the reason why
the condition is often diagnosed late in its clinical course.
Most patients feel well at rest, however, increasingly minor
exercise poses a major problem to the affected. Until re-
cently, PH was not only defined as mPAP ≥ 25 mmHg at
rest, but also as >30 mmHg at exercise [3-5]. However, to
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date only few data supporting this definition is available,
and the normal response to exercise of healthy subjects,
especially of elderly, is not well known. Thus, the defin-
ition of exercise-induced PH was cancelled during the
WHO meeting in Dana Point, 2009 and not re-introduced
in Nice, 2013 [1].
At our PH center at the University Hospital of Zurich,
measurement of pulmonary hemodynamics during exer-
cise by RHC, using a cycle ergometer in supine position, is
performed since 2005.
As data on exercise hemodynamics in healthy people is
mostly available from relatively old studies and data on
PH-affected patients is rare [6,7], we aimed to retrospect-
ively analyze all exercise RHC performed at our center in
order to correlate resting with exercise hemodynamics, to
characterize the differential response to exercise in the
various PH classes, and to investigate the value of exercise
RHC in the upmost mPAP range of normal (from 20 to
24.9 mmHg) formerly labelled as borderline PH. A further
aim was to look at the safety of exercise RHC procedure.
Methods
Study design and study subjects
This is a retrospective, observational study performed at
our referral center for PH. We reviewed all RHC data
from January 2006 until January 2013. Eligible patients
were all those in whom a RHC with additional recording
of exercise hemodynamics was performed. From the total
117 eligible patients we excluded 16 patients because they
were already taking PH specific medical therapy and
the exercise RHC was performed in the follow up after
establishing appropriate targeted therapy (Figure 1). All
patients included in the study (n = 101) were referred
with clinical suspicion of PH, mostly because of exer-
tional dyspnea or progressive diffusion limitation for
carbon monoxide in scleroderma patients, and a diag-
nostic RHC at rest and during exercise was performed.
Methods
By reviewing the medical histories we collected the
hemodynamic data and patients’ characteristics (demo-
graphics, vital signs, PH class according to Dana Point
classification scheme, 6 minute walk distance, and func-
tional limitation [WHO/NYHA class]). In addition, we
looked for possible adverse events during or shortly after
the RHC procedure and gathered follow up data regarding
survival by clinical medical records or contacts to the
treating physicians. RHC was performed in supine pos-
ition using a conventional pulmonary artery catheter and
Edwards Vigilance Monitor for cardiac output measuring
(continuous cardiac output thermodilution catheter). The
usual invasively measured hemodynamic parameters were
recorded. Baseline measurements were recorded after 15
minutes of rest and repeated 5 to 10 minutes later. For
further calculations the mean of these resting values was
taken. For the exercise testing we used a dynamic, symp-
tom limited, step-wise incremental cycling exercise proto-
col in supine position. Patients were challenged by a cycle
Figure 1 Patients and diagnostic groups after right heart catheterization. HFnEF, heart failure with normal ejection fraction, PAH, pulmonary
arterial hypertension; PH, pulmonary hypertension; COPD, chronic obstructive pulmonary disease; CTEPH, chronic thromboembolic pulmonary
hypertension; TPG, transpulmonary pressure gradient.
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ergometry (TheraVital, Medica GMbH, Ravensburg) in su-
pine position starting at 10 watts. The work load was in-
creased every 3 minutes by 10 watts until symptoms
occurred that lead to termination of exercise or in total
15 minutes of exercise was achieved. Data were recorded
every 3 minutes before increasing the work load.
The patients were allocated to different diagnostic
groups according to their resting hemodynamics and
their hemodynamic response to exercise. The following
groups were formed: (1) resting precapillary PH (mPAP ≥
25 mmHg, PAWP < 15 mmHg; PAH group), (2) exercise
precapillary PH (mPAP during exercise > 30 mmHg,
PAWP < 15 mmHg; ePAH group), (3) resting postcapillary
PH (mPAP ≥ 25 mmHg, PAWP >15 mmHg; PVH group),
(4) exercise postcapillary PH (mPAP during exercise > 30
mmHg, PAWP > 15 mmHg; ePVH), (5) exercise out-of-
proportion PH (mPAP during exercise > 30 mmHg,
PAWP > 15 mmHg, transpulmonary gradient (TPG) > 12;
eoPVH group) and (6) no PH (neither at rest, nor at
exercise).
Statistical analysis
All baseline data are summarized by medians and quar-
tiles. Baseline variables by groups were compared using
Mann-Witney-U-Test. P <0.05 was considered signifi-
cant. Statistica 10 (StatSoft, Inc., Tulsa, USA), SPSS 19
and Microsoft Excel (Version 2010) were used.
Ethics
All patients gave their written informed consent to regis-
ter their data for scientific purposes and the study was
approved by the local ethical authorities (KEK 2012-
0125).
Results
A total of 101 patients with exercise performance during
RHC were included. They all underwent catheterization
because of clinical suspicion of PH, mostly due to exer-
tional dyspnea or progressive diffusion limitation for
carbon monoxide in scleroderma patients. The overall
baseline characteristics of these patients are shown in
Table 1 and 2. According to the hemodynamic character-
istics established during RHC the included patients were
allocated to the different groups as described in the
methods section. The absolute numbers in each group are
listed in Figure 1. About one third of patients had resting
PH (PAH or PVH). Out of the two thirds of patients with-
out resting PH 13 patients (20%) suffered from ePAH, 26
had ePVH (39%), and 27 patients (41%) did not have ele-
vated pulmonary pressures at rest or exercise. A high pro-
portion of scleroderma (n = 15, 34% of all included
scleroderma patients) were in the group of ePVH.
A separate clustering was done with patients that pre-
sented with mPAP from 20 to 24.9 mmHg. A total of 29
patients fitted according to their hemodynamics in this
group. A high proportion of these patients (n = 24)
showed an elevation of mPAP above 30 mm Hg during
exercise (83%). Eight patients presented with ePAH
(28%) and 16 patients presented with ePVH (55%), only
5 patients in this cluster had no PH at exercise (17%).
A total of 37 patients had mPAP< 20 mmHg. Intri-
guingly 15 patients in this group presented with exercise
PH forms (40.5%); namely 5 with ePAH, and 10 with
ePVH.
Comparisons between the different PH groups show-
ed mainly a greater variance in the pulmonary hemo-
dynamics in the groups of resting PH, either precapillary
or postcapillary (see Table 3). In precapillary PH groups
we found a greater increase in mPAP during exercise in
PAH compared to the ePAH group. Accordingly, also
right atrial pressure and pulmonary vascular resistance
were higher, arterial oxygen saturation and mixed venous
oxygen saturation were lower in the PAH group. The
mean blood pressure at exercise was higher in the PVH
group compared to non-PH patients. The increase in
mPAP was statistically not different in the postcapillary
PH groups (PVH versus ePVH). The right atrial pressure
and per definition the PAWP were higher in PVH.
Comparison between ePVH and eoPVH was performed.
The baseline characteristics did not show any statistical
differences. The pulmonary hemodynamics were more
compromised in the eoPVH group showing a higher
mPAP and PVR at rest and a greater increase in PVR
during exercise compared to ePVH.
The median follow up for mortality in all patients was
1,024 days (289; 1,287). The length of follow up of each
group as well as deaths and adverse events are shown in
Table 1 Baseline characteristics
Total number of patients, n (%) 101
Female, n (%) 70 (69.3%)
Age, years 61 (52;68)
Relevant clinical diagnosis before Catheter-assessment, n (%)
Scleroderma 44 (44%)
Chronic lung disease 11 (11%)
History of pulmonary embolism 9 (9%)
Sarcoidosis 4 (4%)
HIV 3 (3%)
Other unclear dyspnea 30 (30%)
NYHA/WHO functional class, n (%)
Class I/II 11 (11%)/35 (35%)
Class III/IV 42 (41%)/13 (13%)
Body mass index, kg/m2 25.1 (21.9;28.2)
6 minute walking distance, m 475 (335;539)
Data given as median (quartiles) or number (%). NYHA: New York Heart
Association, WHO: World Health Organization.
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Table 4. The event rate and group size were too small to
establish mortality differences between groups. During
performance of RHC with exercise we encountered no
adverse events and consider the procedure in experi-
enced hands as safe.
Discussion
In this observational study of patients with clinical sus-
picion of PH we found resting PH in 35% of patients.
In 38.6% of patients we detected either precapillary
(ePAH) or postcapillary exercise PH (ePVH) and in
25.7% of patients PH could be excluded. We found a
remarkable number of exercise PH in the scleroderma
patients (ePAH or ePVH), a population well-known for
its highest risk of developing PH. A great number of
ePVH was found in this patient collective. In the cluster
of patients with resting mPAP-values between 20 and
24.9 mmHg, 83% showed exercise PH. The groups of
resting PH forms showed more severe hemodynamic
compromise of the pulmonary vasculature.
The normal pressures in the pulmonary vascular bed
at rest and mainly at exercise are still in discussion. In
early studies of Wood in the 1950s a normal mPAP of
20 mmHg was estimated [7,8]. Actual guidelines define
PH by a cut-off-value of ≥ 25 mmHg, whereas a recent
systematic review showed that the upper limit of normal
is about 20 to 21 mmHg [6]. During exercise the physio-
logical rise in pulmonary pressures is intensively de-
bated. Until the WHO consensus guidelines in 2009, it
was accepted that a mPAP> 30 mmHg during exercise
exceeds the limits of normal [4]. Because of insufficient
data on exercise pulmonary hemodynamics, this defin-
ition did not find its way in the latest guidelines [1]. A
systematic review of historically reported exercise RHC
in presumptively healthy people found an age-dependent
rise in mPAP during exercise. 21% of healthy persons
aged < 50 years reached mPAP-values of > 30 mmHg
and 47% of subjects > 50 years showed a mPAP of > 30
mmHg at maximal exercise [6]. In our study of symp-
tomatic patients with a median age of 61 years, including
a high proportion of patients at highest risk for PH
(scleroderma), nearly 40% of patients reached mPAP-
values above 30 mmHg at relatively low exercise levels
and we strongly believe that this increase was clinically
relevant for the patients’ symptoms. A remarkable large
proportion of patients (83%) with mPAP-values between
20 and 24.9 mmHg are found in the exercise PH groups.
This fact nourishes the suspicion that this group may
suffer from early forms of PH. A signal that even mPAP
values < 20 mmHg may already be associated with patho-
logical exercise pulmonary hemodynamic derives from the
fact that 40% of the symptomatic patients in our study
with a mPAP< 20 mmHg reached values > 30 mmHg dur-
ing exercise. Also the significant rise of PVR during
exercise in the ePAH group versus the no PH group indi-
cates the pathological hemodynamic response of the
pulmonary vascular bed during exercise in these patients.
We found a significant correlation of the change in PVR
with the six-minute walk distance (r = -0.271, p = 0.023
and are thus in line with a meta-analysis by Savarese, who
similarly showed a significant correlation of the change in
PVR with exercise performance measured by the six-
minute walking distance (r = -0.55, p = 0.04). No associ-
ation with clinical events such as death or hospitalization
could be established though [9]. In patients with
chronic obstructive pulmonary disease or pulmonary
Table 2 Patients characteristics according to diagnostic groups
Diagnostic
group
Resting precapillary
PH, PAH (n = 28)
Exercise precapillary
PH, ePAH (n = 13)
Resting
postcapillary
PH, PVH (n = 7)
Exercise postcapillary
PH, ePVH (n = 12)
Exercise postcapillary
out-of-proportion
PH, eoPVH (n = 14)
No PH (n = 27)
Age, years 63.7¶ (58.6; 70.4) 53.9 (51.8; 62.6) 73.4¶ (64.3; 73.8) 61.2 (51.0; 67.4) 61.3 (54.6; 68.3) 53.9 (43.3; 66.0)
Females, n 15 (53.6) 9 (69.2) 6 (85.7) 8 (66.7) 9 (64.3) 23 (85.2)
BMI, kg/m2 25.3¶ (22.3; 27.8) 25.9 (23.2; 28.1) 28.0¶ (24.4; 30.2) 25.1 (21.8; 27.8) 27.3¶ (25.3; 29.7) 22.8 (18.7; 25.4)
NYHA class
II/III/IV, n
28 (100) 12 (92.3) 7 (100) 10 (83.3) 12 (85.7) 21 (77.8)
6MWD, m 459.5 (296; 504) 500 (414; 552) 437 (339; 450) 566 (460; 603) 490 (330; 532) 450 (300; 540)
SpO2 after
6MWD, %
90 (80; 93) 93.5 (82; 96) 95 (95; 96) 96 (94; 98) 94 (89; 96) 94 (89; 95)
HR after
6MWD, bpm
109 (91; 127) 104 (83; 115) 98 (88; 109) 104 (91; 116) 118 (108; 137) 103 (100; 120)
SBP after
6MWD, mmHg
138 (120; 161) 131 (120; 142) 175 (154; 198) 130 (116; 154) 155 (140; 160) 139 (138; 158)
Data given as median (quartiles) or number (%). ¶= p <0.05 compared to patients with no PH. No significant differences between exercise postcapillary PH and
exercise postcapillary out-of-proportion PH were detected.
6MWD, Six minute walk distance, BMI, Body mass index; ePAH, Exercise precapillary pulmonary hypertension; eoPVH, Exercise postcapillary out-of-proportion pulmonary
hypertension; ePVH, Exercise postcapillary pulmonary hypertension; HR, Heart rate; NYHA, New York Heart Association, PAH, Pulmonary arterial hypertension; PH,
Pulmonary hypertension; PVH, Postcapillary pulmonary hypertension; SpO2, Peripheral oxygen saturation; SBP, Systemic blood pressure.
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Table 3 Hemodynamic data according to diagnostic groups
Diagnostic group Resting
precapillary PH,
PAH (n = 28)
Exercise
precapillary PH,
ePAH (n = 13)
Resting
postcapillary PH,
PVH (n = 7)
Exercise
postcapillary PH,
ePVH (n = 12)
Exercise postcapillary
out-of-proportion
PH, eoPVH (n = 14)
No PH
(n = 27)
Resting hemodynamics
HR, bpm 79 (69; 86.5) 71.5 (66; 83) 79 (74; 84) 70.5¶ (61; 74) 76 (70; 83) 78 (70; 86)
Mean BP, mmHg 91 (85; 104) 87 (78; 91) 110 (78; 126) 93 (86; 101) 95 (84; 101) 90 (86; 104)
Mean PAP, mmHg 32¶,* (26; 44) 20¶ (18; 21) 30¶,* (28; 34) 19§ (15; 22) 22¶ (19; 23) 15 (14; 18)
Diastolic PAP, mmHg 23¶,* (18; 31) 14¶ (12; 15) 21¶,* (19; 24) 12 (10; 15) 15¶ (13; 18) 11 (10; 14)
RAP, mmHg 8 (4.5; 9.5) 6 (4; 7) 9¶,* (7; 10) 5 (3; 8) 6 (4; 9) 5 (4; 7)
PAWP, mmHg 12¶,* (10; 13) 8 (8; 11) 17¶,* (17; 19) 12 (8; 14) 11¶ (9; 12) 8 (7; 10)
TPG, mmHg 23¶,* (17; 28) 9¶ (9; 12) 13¶,* (11; 14) 7§ (5; 8) 9¶ (9; 12) 7 (6; 9)
DPG, mmHg 10¶,* (8; 17) 5¶ (3; 7) 4 (1; 6) 1¶,§ (0; 3) 3 (2; 6) 2 (1; 3)
CI, l/min/m-2 3.0 (2.5; 3.5) 3.4 (2.8; 3.9) 3.2 (3.0; 4.8) 3.0 (2.75; 3.7) 3.5 (3.0; 4.0) 3.0 (2.7; 4.0)
CO, l/min 5.4 (4.1; 6.7) 6.3 (4.9; 7.2) 6.0 (5.0; 10.8) 5.3 (4.6; 7.0) 6.7¶ (5.5; 7.4) 5.1 (4.2; 6.8)
PVR, dynes*s*m-2 330¶,* (248; 415) 135 (112; 145) 193 (105; 247) 83¶,§ (63; 95) 122 (97; 175) 109 (90; 158)
SVR, dynes*s*m-2 1296 (1018; 1656) 1026 (898; 1382) 1031 (717; 1875) 1263 (948; 1562) 1196 (1026; 1331) 1340 (1101; 1761)
SaO2, % 90.5
¶,* (87.8; 93.9) 95.0 (93.0; 95.3) 94.0 (93.0; 95.0) 94.8 (92.7; 96.0) 94.8 (93.0; 95.3) 94.8 (93.0; 96.0)
PaO2, kPA 8.2
¶,* (7.6; 9.6) 10.6 (9.2; 11.7) 9.5¶ (8.9; 10.00) 10.2 (9.0; 11.7) 10.3 (9.4; 11.4) 11.4 (10.1; 12.2)
PaCO2, kPA 4.60 (4.32; 5.35) 4.65
¶ (4.51; 4.80) 4.70 (4.49; 5.30) 4.85 (4.50; 5.27) 5.13 (4.60; 5.30) 5.05 (4.75; 5.40)
SmvO2, % 66.1
¶,* (60.6; 70.5) 71.0 (69.0; 74.4) 70.0 (65.0; 71.0) 71.6 (68.4; 76.1) 71.4 (69.1; 73.5) 70.0 (65.4; 72.8)
Hemodynamics during supine maximal cycling exercise
Watt achieved 30 (20; 50) 30 (20; 40) 30 (20; 30) 30 (20; 50) 30 (20; 45) 30 (20; 40)
HR, bpm 110 (103; 123) 102 (98; 116) 111 (101; 118) 105 (98; 122) 116.5 (106; 122) 120 (101; 126)
Mean BP, mmHg 115 (101; 125) 107 (92; 114) 128¶ (102; 158) 107 (93; 120) 107 (103; 115) 101 (91; 113)
Mean PAP, mmHg 58¶,* (50; 66) 35¶ (32; 37) 47¶,* (42; 65) 36¶ (31; 41) 42¶ (38; 43) 24 (18; 27)
Increase in mPAP with
exercise, mmHg
20¶,* (16; 30) 14¶(13; 19) 17¶(12; 31) 16¶(12; 25) 19¶ (14.7; 21) 7 (3; 9)
Increase in mPAP
per Watt, mmHg
0.73¶ (0.53; 1.05) 0.47¶ (0.33; 0.74) 0.57¶ (0.40; 1.10) 0.48¶ (0.36; 0.77) 0.66¶ (0.35; 0.85) 0.20 (0.10; 0.33)
Diastolic PAP, mmHg 40¶,* (32; 45) 24¶ (22; 25) 30¶ (26; 40) 27¶ (24; 30) 30¶ (25; 31) 16 (12; 18)
RAP, mmHg 12¶,* (7; 17) 7 (3; 8) 16¶,* (9; 18) 10¶ (7; 11) 8¶ (6; 9) 5 (2; 7)
PAWP, mmHg 16¶,* (13; 21) 12 (10; 14) 32¶,* (27; 36) 26.5¶ (23; 34) 21.5¶ (17; 28) 10 (7; 15)
TPG, mmHg 41¶,* (34; 45) 22¶ (21; 29) 16 (8; 30) 9¶,§ (6; 12) 18¶ (16; 21) 12 (9; 14)
DPG, mmHg 21¶,* (13; 29) 11¶ (10; 13) 1 (-9; 7) -1.5¶,§ (-6.5; 2.0) 5.5 (3; 9) 4 (2; 6)
CI, l/min/m-2 3.8 (3.0; 4.3) 4.0 (3.7; 4.7) 3.7 (3.3; 5.4) 3.7 (3.2; 4.1) 4.2 (3; 4.8) 3.8 (3.1; 4.3)
CO, l/min 6.8 (5.0; 8.3) 7.2 (6.7; 8.4) 6.5 (5.6; 12.1) 6.5 (5.5; 8.0) 7.06 (6.44; 8.83) 6.4 (4.8; 8.3)
PVR, dynes*s*m-2 487¶,* (398; 534) 251¶ (207; 335) 163 (100; 198) 97¶,§ (82; 119) 173.5 (148; 227) 139 (107; 229)
Delta PVR, dynes*s*m-2 126¶ (68; 208) 103¶ (73; 167) 15 (-89; 93) 16¶,§ (-9; 36) 57 (37; 97) 34 (11; 89)
SVR, dynes*s*m-2 1186 (866; 1679) 1031 (907; 1077) 1413 (739; 1541) 1164 (903; 1327) 989.5 (911; 1251) 1222 (933; 1755)
SaO2, % 88.0
¶,* (80.0; 94.0) 95.0 (86.0; 96.0) 96.0 (94.0; 97.0) 94 (93; 95) 93.4¶ (91; 94.5) 96.0 (95.0; 97.0)
SmvO2, % 36.5
¶,* (28.2; 43.5) 52.0 (38.0; 55.0) 45.0 (24.0; 50.0) 44.5 (33.5; 57.5) 50 (36; 58) 48.0 (40.0; 55.0)
Data given as median (quartiles) or number (%). ¶= p < .05 compared to patients with no PH. *= p < .05 compared to patients with appropriate exercise PH (either
resting precapillary PH compared to exercise precapillary PH, or resting postcapillary PH compared to exercise postcapillary PH). §= p < .05 compared to exercise
out-of-proportion PH.
BP, Blood pressure; CI, Cardiac index; CO, Cardiac output; DPG, Diastolic pressure gradient; ePAH, Exercise precapillary pulmonary hypertension; eoPVH, Exercise
postcapillary out-of-proportion pulmonary hypertension; ePVH, Exercise postcapillary pulmonary hypertension; HR, Heart rate; PaO2, Arterial oxygen partial pressure;
PaCO2, Arterial carbon dioxide partial pressure; PAH, Pulmonary arterial hypertension; PAP, Pulmonary arterial pressure; PAWP, Pulmonary artery wedge pressure; PH,
Pulmonary hypertension; PVH, Postcapillary pulmonary hypertension; PVR, Pulmonary vascular resistance; RAP, Right atrial pressure; SaO2, Arterial oxygen saturation;
SmvO2, Mixed venous oxygen saturation; SVR, Systemic vascular resistance; TPG, Transpulmonary pressure gradient.
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fibrosis resting mPAP values of > 17-18 mmHg were
already associated with increased mortality or clinical
worsening [10,11].
The impact of age and its physiological effect on exer-
cise pulmonary hemodynamics is difficult to establish in
lack of data in healthy and diseased subjects. Recently,
Whyte published data on 38 patients aged < 50 years
and free of PH who underwent resting and exercise
RHC. Out of these 38 patients, 63% developed mPAP-
values > 30 mmHg at mild-to-moderate exercise (< 60
Watt). Compared to healthy subjects not increasing their
mPAP above 30 mmHg, those with a significant in-
crease in mPAP showed higher resting mPAP and higher
PVR [12]. In another study of symptomatic patients re-
ferred for RHC, a greater number showed PVH (48%).
From those classified as PAH 84% suffered from ePAH.
The mean age of this group was 58.8 years [13]. In a
registry analysis of Condliffe in connective tissue
disease-associated PAH the proportion of patients with
ePAH was 11.4% and about 19% of them progressed
within 2 to 3 years to PAH. Progression to PAH in this
scleroderma cohort occurred in 60% of patients with
ePAH who died in the follow up period of maximal 6
years [14]. We believe that further studies have to shed
light on this issue, especially on the age-dependency of
cut-off values during exercise.
In our scleroderma subgroup, a collective that is at
highest risk for developing PH, we found pre- and post-
capillary PH-forms. A high number suffered from ePVH
without signs of disturbances in the pulmonary vascular
bed (not out-of-proportion). A similarly high proportion
of ePVH was found in a scleroderma collective by
Saggard with 21% of patients (n = 54, resting PH was ex-
cluded) [15]. This underlines the need to collect more
information on exercise pulmonary hemodynamics dur-
ing RHC, as echocardiography would probably misclas-
sify some patients since no PAWP can accurately be
determined. None of the 44 scleroderma patients in this
collective had postcapillary PH at rest, but a remarkable
1/3 had ePVH. This might explain why these patients
were symptomatic with dyspnea and thus scheduled for
RHC. However, the course of this entity and the best
treatment options need to be better defined. Further ob-
servational and treatment studies will show if the classi-
fication by exercise hemodynamics is able to separate
patients according to treatment response and outcome.
Our report on exercise RHC in real life illustrates the
difficulties of daily clinical practice to classify patients.
Too little is known about the exercise PH forms and
their clinical course or benefit of treatment with PAH-
specific therapy. Can an elevated mPAP> 30 mmHg at
maximal exercise of 20 Watt in a symptomatic patient with
scleroderma be compared to a similar absolute mPAP in-
crease in a healthy patient at 150 Watt? In our and others
opinion the answer would be no [7]. Should we treat ePAH
or wait until PAH will develop years later? What does post-
capillary out-of-proportion PH during exercise signify?
Our real-life data show that the classification of patients
with exertional dyspnea into PH classes or subcategories of
formerly labelled borderline PH or exercise PH is difficult
and more a continuum than clearly distinguished groups.
We hope that with future prospective studies more insight
can be gathered to this clinically important issue.
Performing maximal symptom-limited exercise RHC
in sometimes highly symptomatic PH patients was abso-
lutely safe in our collective, as we did not encounter any
adverse events. As others, we believe that in experienced
hands this diagnostic tool is safe and can be performed
in clinical routine in the diagnostic work-up of patients
with suspicion of PH [16,17]. However, a problem in
clinical practice and research is that no standardized
protocols for exercise RHC testing are available. Import-
ant issues in performing exercise RHC are the type of
exercise (dynamic vs. static), the increase in work load
(linear, step-wise) and the body position during exercise.
We used a completely supine position with a bicycle
fixed at the end of the patient bed. In this position, sub-
jects will perform considerably less work load compared
to up-right cycling. However, the supine position has the
advantage of a similar and calm thorax position for mea-
surements. In general, it is accepted that exercise should
rather be dynamic to avoid increases in systemic resist-
ance and that intrathoracic pressure swings should be
carefully reduced due to their effects on the pressure
Table 4 Follow up, adverse events and mortality data
Diagnostic group Resting
precapillary
PH (n = 28)
Exercise
precapillary
PH (n = 13)
Resting
postcapillary
PH (n = 7)
Exercise
postcapillary
PH (n = 12)
Exercise postcapillary
out-of-proportion
PH (n = 14)
No PH
(n = 27)
Follow-up days, n 1,080 (246; 1231) 1,031 (366; 1346) 1,080 (279; 1290) 718 (321; 1440) 1,112 (542; 1332) 714 (282; 1241)
Death, n 1 1 1 1 0 2
Lung transplantation, n 3 0 0 0 0 0
Pulmonary endarterectomy, n 2 1 0 0 0 0
Adverse events at RHC, n 0 0 0 0 0 0
A low event rate precludes statistical comparison. PH, Pulmonary hypertension, RHC, Right heart catheterization.
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transducers in the pulmonary vasculature [18]. There-
fore, isotonic arm exercise as it is performed in some
catheter laboratories, should be discouraged [19].
Limitations of our study are, apart from the single-
center experience and the retrospective design, the rather
small number of patients in the different groups and the
relatively short follow up with very few events, which did
not allow estimates on prognosis. The patients in our col-
lective where slightly overweight (mean BMI 25.1 kg/m2),
which corresponds to the Swiss general population and
other PH-collectives published. Intrinsically to the trial de-
sign, we do not have a healthy matched control group and
we were thus limited to compare symptomatic patients ac-
cording to their hemodynamic profile. Therefore, insight
in normal physiological response is limited.
Conclusion
In this real-life experience in symptomatic patients under-
going exercise RHC for suspected PH, we found that exer-
cise RHC is safe without any adverse events. Patients with
diseases known to be associated with PH, such as sclero-
derma, were found in all hemodynamically defined
groups, and this underscores the importance of RHC in
the diagnosis of PH. The facts that the vast majority of pa-
tients with mPAP-values between 20 and 24.9 mmHg at
rest develop exercise PH and that patients with resting PH
are older strongly argue for exercise PH as a precursor of
resting PH. Whether an earlier treatment start in patients
with exercise PH (especially ePAH) would stabilize the
disease should be addressed in future studies.
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